This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeCDC RecommendationAbout RSVAbout ABRYSVOHeading

Example of description text sitting alongside header

Efficacy ProfileSafety ProfileDosing, Storage, ReconstitutionOrder ABRYSVOResourcesResourcesHealth Plan CoverageRequest A RepEventsMaterialsVideos
Prescribing InformationIndications Older AdultPatient Site
ABRYSVO®: the only maternal RSV vaccine—CDC-recommended and ACOG-supported—for immunization of pregnant people at 32 weeks and 0 days’ through 36 weeks and 6 days’ gestation from September to January in most regions.1-3*Click here for the full MMWR publication.
Click here for the ACOG Practice Advisory.

*In jurisdictions with RSV seasonality that differs (Alaska, southern Florida, Guam, Hawaii, Puerto Rico, US-affiliated Pacific Islands, and US Virgin Islands), providers should follow state, local, or territorial guidance on timing of ABRYSVO. EVERY BREATH MATTERS. Don't let RSV take her baby's breath away.

Talk to your pregnant patients about maternal vaccination with ABRYSVO to reduce their newborns’ risk of RSV from birth through 6 months.1



ABRYSVO is an RSV vaccine indicated for immunization of pregnant individuals at 32 through 36 weeks gestational age.1

View Clinical DataLoadingDiscover ABRYSVOABRYSVO is the first opportunity to help protect their babies against RSV via maternal immunization1ABRYSVO Data

Explore the efficacy profile in infants, as well as the safety profiles of this RSV vaccine in pregnant women and infants.

View DataLoading Respiratory Syncytial Virus

Learn about RSV, a common virus that’s particularly dangerous for infants.6
 

 Learn MoreLoading ABRYSVO Reconstitution

See Pfizer's convenient, needle-free‡ reconstitution kit.1


 

ReferencesNeedle required for intramuscular injection is not included. Learn MoreLoading Accessing ABRYSVO

Learn more about costs and coverage for this RSV vaccine for appropriate pregnant women.1

 See DetailsLoadingResources

Discover helpful materials for you and your pregnant patients about ABRYSVO — the first opportunity to help protect newborns from RSV via maternal immunization.1

Loading View CDC Recommendation LoadingACOG=American College of Obstetricians and Gynecologists; CDC=Centers for Disease Control and Prevention; MMWR=Morbidity and Mortality Weekly Report;
RSV=respiratory syncytial virus.ACOG=American College of Obstetricians and Gynecologists; CDC=Centers for Disease Control and Prevention; MMWR=Morbidity and Mortality Weekly Report; RSV=respiratory syncytial virus.
Receive Updates About ABRYSVO Register NowLoading Request a Pfizer Sales Representative Connect Now Loading Live Pfizer Connect Health and Science Representative

Mon-Fri, 9 am – 5 pm ET

 Call 1-844-966-5127 Loading
Receive Updates About ABRYSVO Register NowLoading Request a Pfizer Sales Representative Connect Now Loading Live Pfizer Connect Health and Science Representative

Mon-Fri, 9 am – 5 pm ET

 Call 1-844-966-5127 Loading

References:

ABRYSVO (Respiratory Syncytial Virus Vaccine) Prescribing Information. Pfizer Inc; August 2023.Fleming-Dutra KE, Jones JM, Roper LE, et al. Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72:1115–1122.
doi:10.15585/mmwr.mm7241e1American College of Obstetricians and Gynecologists. Maternal Respiratory Syncytial Virus Vaccination. Practice Advisory. September 2023. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2023/09/maternal-respiratory-syncytial-virus-vaccinationGreen LJ, Mackillop LH, Salvi D, et al. Gestation-specific vital sign reference ranges in pregnancy. Obstet Gynecol. 2020;135(3):653-664.Data on file. Pfizer Inc.Parikh RC, McLaurin KK, Margulis AV, et al. Chronologic age at hospitalization for respiratory syncytial virus among preterm and term infants in the United States. Infect Dis Ther. 2017;6(4):477-486. doi:10.1007/s40121-017-0167-9

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-A1G-USA-0940
You are now leaving PfizerProYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 
PP-MCL-USA-0367
IndicationsABRYSVO is a vaccine indicated for:
 
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age

Please click here for full Prescribing Information.
Important Safety Information
  • Do not administer ABRYSVO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of ABRYSVO
  • A numerical imbalance in preterm births was observed compared to placebo in 2 clinical studies. Data are insufficient to establish or exclude a causal relationship between preterm birth and ABRYSVO. To avoid potential risk of preterm birth with use of ABRYSVO before 32 weeks of gestation, administer to pregnant individuals at 32 through 36 weeks gestational age 
  • Appropriate medical treatment must be available in case of an anaphylactic reaction
  • Syncope (fainting) may occur in association with administration of injectable vaccines, including ABRYSVO. Procedures should be in place to avoid injury from fainting
  • Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to ABRYSVO
  • Vaccination with ABRYSVO may not protect all vaccine recipients
  • In clinical trials with older adults, the most commonly reported (≥10%) adverse reactions were fatigue (15.5%), headache (12.8%), pain at the injection site (10.5%), and muscle pain (10.1%)
  • In clinical trials with pregnant individuals, the most commonly reported (≥10%) adverse reactions were pain at the injection site (40.6%), headache (31.0%), muscle pain (26.5%), and nausea (20.0%)
  • In clinical trials with infants born to pregnant individuals, low birth weight (5.1% ABRYSVO versus 4.4% placebo) and neonatal jaundice (7.2% ABRYSVO versus 6.7% placebo) were observed
Individuals who received ABRYSVO during pregnancy are encouraged to contact 1-800-616-3791 to enroll in a Pregnancy Exposure Registry.

Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for ABRYSVO.Indications
ABRYSVO is a vaccine indicated for:
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age